Kura Oncology (KURA)
(Delayed Data from NSDQ)
$21.76 USD
-0.30 (-1.36%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $21.79 +0.03 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 141 - 160 ( 258 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Rejuventated Focus on HRAS Targeting at Kura
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
KOMET-001 Partial Clinical Hold a Class Effect;Target Adjusted to $32 on Likely Temporary Impact
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Ph 1b Enrollment and RP2D for KO-539 on Track for Q1:22
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; ASH Updates Shortly, Then Prepping for Strong 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Abstracts and Sessions Relevant to Covered Companies at AACR-NCI-EORTC
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; KO-539 Expansion in Earnest as Visibility Coming Back to Farnesyl Transferase Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; KO-539 Remains on Aggressive Track;
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Tipifarnib Stays KURRENT With Fresh Clinical Collaboration
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for KURA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
KO-539 Programs Expands as Expected; First Patient Dosed in Phase 1b Study in r/r AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; AML Expansion Cohorts Set to Initiate Mid-Year
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; KO-539 Program Expansion With Clear Focus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Additional Validation for Menin Inhibitors, but SNDX-5613 Profile Struggles
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R